In head and neck squamous cell carcinoma, the NGF–TrkA axis...; anticipated on-target effects of NGF/TrkA inhibition include sensory paresthesias/hypoalgesia, mitigated by dose titration, intermittent scheduling, local-field delivery when feasible, and rescue with non-opioid analgesic algorithms (73, 74). This evidence concerns the gene NGF and head and neck squamous cell carcinoma.